Launch Event: Global Study on the Value of Self-Care 19/05/2022 Editorial team A one-of-a-kind global study demonstrating the value of self-care will be released this week during a side event of the World Health Organization’s World Health Assembly in Geneva. The study, “Self-Care Socio-Economic Research,” was produced by the Global Self-Care Federation (GSCF). “Given the proven benefits and efficiency gains that self-care delivers, it is clear self-care […] Continue reading -> UN Environment Programme Joins WHO Alliance to Advance One Health Approach 18/03/2022 Editorial team UN Environment has joined a three-way alliance with the Food and Agriculture Organization, the World Animal Health Organization (OIE), and WHO to advance “One-Health” solutions to both ecosystem degradation and pandemic threats, leaders of the four agencies said on Friday. The statement followed a meeting this week of the Tripartite FAO, WHO and OIE partnership […] Continue reading -> FDA Authorizes First COVID-19 Test For Self-Testing At Home 18/11/2020 Editorial team The U.S. Food and Drug Administration has issued an emergency use authorization (EUA) for the first COVID-19 diagnostic test for self-testing at home and that provides rapid results. The Lucira COVID-19 All-In-One Test Kit is a molecular-based single use test that is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19. “While COVID-19 diagnostic […] Continue reading -> Breakthrough Ingestible Sensor Lets Patients Take Tuberculosis Drugs Independently 04/10/2019 Press release San Diego, US (4 October 2019) – A trial involving a safe, novel ingestible sensor connected to a paired mobile device that lets medical staff remotely monitor patients’ intake of tuberculosis (TB) medicine, has shown better results than directly observed therapy (DOT), where a healthcare worker watches the patient swallow medication, leading researchers to suggest […] Continue reading -> The Medicines Patent Pool Publishes Intellectual Property Status Of 18 Drugs Added To WHO Essential Medicines List 03/10/2019 Press release [The Medicines Patent Pool] Geneva (2 October 2019) — The Medicines Patent Pool today announced the first of a two-step update of its database MedsPaL to include additional patented small molecule medicines following the publication of the World Health Organization (WHO)’s updated Model List of Essential Medicines (EML) in July. Launched in 2016, MedsPaL is […] Continue reading -> FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis 15/08/2019 Press release [TB Alliance] NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis (TB).1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) […] Continue reading -> UNAIDS welcomes the appointment of Winnie Byanyima as its new Executive Director 15/08/2019 Press release [UNAIDS] GENEVA, 14 August 2019—UNAIDS warmly welcomes the appointment of Winnie Byanyima as its new Executive Director. Ms Byanyima has more than 30 years of experience in political leadership, diplomacy and humanitarian engagement. “I am honoured to be joining UNAIDS as the Executive Director at such a critical time in the response to HIV,” said […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Patients treated for visceral leishmaniasis can still transmit the disease even after completing treatment, study shows 22/07/2019 Editorial team [DNDi Press Release] Geneva/New Delhi – 22 July 2019 The results of an innovative “infectivity” study conducted by the Drugs for Neglected Diseases initiative (DNDi) and the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) confirm that people successfully treated for visceral leishmaniasis in South Asia can still infect others if they develop a skin condition known […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
UN Environment Programme Joins WHO Alliance to Advance One Health Approach 18/03/2022 Editorial team UN Environment has joined a three-way alliance with the Food and Agriculture Organization, the World Animal Health Organization (OIE), and WHO to advance “One-Health” solutions to both ecosystem degradation and pandemic threats, leaders of the four agencies said on Friday. The statement followed a meeting this week of the Tripartite FAO, WHO and OIE partnership […] Continue reading -> FDA Authorizes First COVID-19 Test For Self-Testing At Home 18/11/2020 Editorial team The U.S. Food and Drug Administration has issued an emergency use authorization (EUA) for the first COVID-19 diagnostic test for self-testing at home and that provides rapid results. The Lucira COVID-19 All-In-One Test Kit is a molecular-based single use test that is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19. “While COVID-19 diagnostic […] Continue reading -> Breakthrough Ingestible Sensor Lets Patients Take Tuberculosis Drugs Independently 04/10/2019 Press release San Diego, US (4 October 2019) – A trial involving a safe, novel ingestible sensor connected to a paired mobile device that lets medical staff remotely monitor patients’ intake of tuberculosis (TB) medicine, has shown better results than directly observed therapy (DOT), where a healthcare worker watches the patient swallow medication, leading researchers to suggest […] Continue reading -> The Medicines Patent Pool Publishes Intellectual Property Status Of 18 Drugs Added To WHO Essential Medicines List 03/10/2019 Press release [The Medicines Patent Pool] Geneva (2 October 2019) — The Medicines Patent Pool today announced the first of a two-step update of its database MedsPaL to include additional patented small molecule medicines following the publication of the World Health Organization (WHO)’s updated Model List of Essential Medicines (EML) in July. Launched in 2016, MedsPaL is […] Continue reading -> FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis 15/08/2019 Press release [TB Alliance] NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis (TB).1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) […] Continue reading -> UNAIDS welcomes the appointment of Winnie Byanyima as its new Executive Director 15/08/2019 Press release [UNAIDS] GENEVA, 14 August 2019—UNAIDS warmly welcomes the appointment of Winnie Byanyima as its new Executive Director. Ms Byanyima has more than 30 years of experience in political leadership, diplomacy and humanitarian engagement. “I am honoured to be joining UNAIDS as the Executive Director at such a critical time in the response to HIV,” said […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Patients treated for visceral leishmaniasis can still transmit the disease even after completing treatment, study shows 22/07/2019 Editorial team [DNDi Press Release] Geneva/New Delhi – 22 July 2019 The results of an innovative “infectivity” study conducted by the Drugs for Neglected Diseases initiative (DNDi) and the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) confirm that people successfully treated for visceral leishmaniasis in South Asia can still infect others if they develop a skin condition known […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
FDA Authorizes First COVID-19 Test For Self-Testing At Home 18/11/2020 Editorial team The U.S. Food and Drug Administration has issued an emergency use authorization (EUA) for the first COVID-19 diagnostic test for self-testing at home and that provides rapid results. The Lucira COVID-19 All-In-One Test Kit is a molecular-based single use test that is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19. “While COVID-19 diagnostic […] Continue reading -> Breakthrough Ingestible Sensor Lets Patients Take Tuberculosis Drugs Independently 04/10/2019 Press release San Diego, US (4 October 2019) – A trial involving a safe, novel ingestible sensor connected to a paired mobile device that lets medical staff remotely monitor patients’ intake of tuberculosis (TB) medicine, has shown better results than directly observed therapy (DOT), where a healthcare worker watches the patient swallow medication, leading researchers to suggest […] Continue reading -> The Medicines Patent Pool Publishes Intellectual Property Status Of 18 Drugs Added To WHO Essential Medicines List 03/10/2019 Press release [The Medicines Patent Pool] Geneva (2 October 2019) — The Medicines Patent Pool today announced the first of a two-step update of its database MedsPaL to include additional patented small molecule medicines following the publication of the World Health Organization (WHO)’s updated Model List of Essential Medicines (EML) in July. Launched in 2016, MedsPaL is […] Continue reading -> FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis 15/08/2019 Press release [TB Alliance] NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis (TB).1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) […] Continue reading -> UNAIDS welcomes the appointment of Winnie Byanyima as its new Executive Director 15/08/2019 Press release [UNAIDS] GENEVA, 14 August 2019—UNAIDS warmly welcomes the appointment of Winnie Byanyima as its new Executive Director. Ms Byanyima has more than 30 years of experience in political leadership, diplomacy and humanitarian engagement. “I am honoured to be joining UNAIDS as the Executive Director at such a critical time in the response to HIV,” said […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Patients treated for visceral leishmaniasis can still transmit the disease even after completing treatment, study shows 22/07/2019 Editorial team [DNDi Press Release] Geneva/New Delhi – 22 July 2019 The results of an innovative “infectivity” study conducted by the Drugs for Neglected Diseases initiative (DNDi) and the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) confirm that people successfully treated for visceral leishmaniasis in South Asia can still infect others if they develop a skin condition known […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Breakthrough Ingestible Sensor Lets Patients Take Tuberculosis Drugs Independently 04/10/2019 Press release San Diego, US (4 October 2019) – A trial involving a safe, novel ingestible sensor connected to a paired mobile device that lets medical staff remotely monitor patients’ intake of tuberculosis (TB) medicine, has shown better results than directly observed therapy (DOT), where a healthcare worker watches the patient swallow medication, leading researchers to suggest […] Continue reading -> The Medicines Patent Pool Publishes Intellectual Property Status Of 18 Drugs Added To WHO Essential Medicines List 03/10/2019 Press release [The Medicines Patent Pool] Geneva (2 October 2019) — The Medicines Patent Pool today announced the first of a two-step update of its database MedsPaL to include additional patented small molecule medicines following the publication of the World Health Organization (WHO)’s updated Model List of Essential Medicines (EML) in July. Launched in 2016, MedsPaL is […] Continue reading -> FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis 15/08/2019 Press release [TB Alliance] NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis (TB).1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) […] Continue reading -> UNAIDS welcomes the appointment of Winnie Byanyima as its new Executive Director 15/08/2019 Press release [UNAIDS] GENEVA, 14 August 2019—UNAIDS warmly welcomes the appointment of Winnie Byanyima as its new Executive Director. Ms Byanyima has more than 30 years of experience in political leadership, diplomacy and humanitarian engagement. “I am honoured to be joining UNAIDS as the Executive Director at such a critical time in the response to HIV,” said […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Patients treated for visceral leishmaniasis can still transmit the disease even after completing treatment, study shows 22/07/2019 Editorial team [DNDi Press Release] Geneva/New Delhi – 22 July 2019 The results of an innovative “infectivity” study conducted by the Drugs for Neglected Diseases initiative (DNDi) and the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) confirm that people successfully treated for visceral leishmaniasis in South Asia can still infect others if they develop a skin condition known […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
The Medicines Patent Pool Publishes Intellectual Property Status Of 18 Drugs Added To WHO Essential Medicines List 03/10/2019 Press release [The Medicines Patent Pool] Geneva (2 October 2019) — The Medicines Patent Pool today announced the first of a two-step update of its database MedsPaL to include additional patented small molecule medicines following the publication of the World Health Organization (WHO)’s updated Model List of Essential Medicines (EML) in July. Launched in 2016, MedsPaL is […] Continue reading -> FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis 15/08/2019 Press release [TB Alliance] NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis (TB).1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) […] Continue reading -> UNAIDS welcomes the appointment of Winnie Byanyima as its new Executive Director 15/08/2019 Press release [UNAIDS] GENEVA, 14 August 2019—UNAIDS warmly welcomes the appointment of Winnie Byanyima as its new Executive Director. Ms Byanyima has more than 30 years of experience in political leadership, diplomacy and humanitarian engagement. “I am honoured to be joining UNAIDS as the Executive Director at such a critical time in the response to HIV,” said […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Patients treated for visceral leishmaniasis can still transmit the disease even after completing treatment, study shows 22/07/2019 Editorial team [DNDi Press Release] Geneva/New Delhi – 22 July 2019 The results of an innovative “infectivity” study conducted by the Drugs for Neglected Diseases initiative (DNDi) and the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) confirm that people successfully treated for visceral leishmaniasis in South Asia can still infect others if they develop a skin condition known […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis 15/08/2019 Press release [TB Alliance] NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis (TB).1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) […] Continue reading -> UNAIDS welcomes the appointment of Winnie Byanyima as its new Executive Director 15/08/2019 Press release [UNAIDS] GENEVA, 14 August 2019—UNAIDS warmly welcomes the appointment of Winnie Byanyima as its new Executive Director. Ms Byanyima has more than 30 years of experience in political leadership, diplomacy and humanitarian engagement. “I am honoured to be joining UNAIDS as the Executive Director at such a critical time in the response to HIV,” said […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Patients treated for visceral leishmaniasis can still transmit the disease even after completing treatment, study shows 22/07/2019 Editorial team [DNDi Press Release] Geneva/New Delhi – 22 July 2019 The results of an innovative “infectivity” study conducted by the Drugs for Neglected Diseases initiative (DNDi) and the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) confirm that people successfully treated for visceral leishmaniasis in South Asia can still infect others if they develop a skin condition known […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
UNAIDS welcomes the appointment of Winnie Byanyima as its new Executive Director 15/08/2019 Press release [UNAIDS] GENEVA, 14 August 2019—UNAIDS warmly welcomes the appointment of Winnie Byanyima as its new Executive Director. Ms Byanyima has more than 30 years of experience in political leadership, diplomacy and humanitarian engagement. “I am honoured to be joining UNAIDS as the Executive Director at such a critical time in the response to HIV,” said […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Patients treated for visceral leishmaniasis can still transmit the disease even after completing treatment, study shows 22/07/2019 Editorial team [DNDi Press Release] Geneva/New Delhi – 22 July 2019 The results of an innovative “infectivity” study conducted by the Drugs for Neglected Diseases initiative (DNDi) and the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) confirm that people successfully treated for visceral leishmaniasis in South Asia can still infect others if they develop a skin condition known […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Patients treated for visceral leishmaniasis can still transmit the disease even after completing treatment, study shows 22/07/2019 Editorial team [DNDi Press Release] Geneva/New Delhi – 22 July 2019 The results of an innovative “infectivity” study conducted by the Drugs for Neglected Diseases initiative (DNDi) and the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) confirm that people successfully treated for visceral leishmaniasis in South Asia can still infect others if they develop a skin condition known […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Patients treated for visceral leishmaniasis can still transmit the disease even after completing treatment, study shows 22/07/2019 Editorial team [DNDi Press Release] Geneva/New Delhi – 22 July 2019 The results of an innovative “infectivity” study conducted by the Drugs for Neglected Diseases initiative (DNDi) and the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) confirm that people successfully treated for visceral leishmaniasis in South Asia can still infect others if they develop a skin condition known […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Patients treated for visceral leishmaniasis can still transmit the disease even after completing treatment, study shows 22/07/2019 Editorial team [DNDi Press Release] Geneva/New Delhi – 22 July 2019 The results of an innovative “infectivity” study conducted by the Drugs for Neglected Diseases initiative (DNDi) and the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) confirm that people successfully treated for visceral leishmaniasis in South Asia can still infect others if they develop a skin condition known […] Continue reading -> Posts navigation Older posts